Zhejiang Shengda Bio-Pharm Co., Ltd. (SHA:603079)
China · Delayed Price · Currency is CNY 15.11
-0.17 (-1.11%)
May 21, 2026, 3:00 PM CST
SHA:603079 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 826.66 | 840.67 | 826.61 | 725.46 | 736.96 | 788.5 |
Other Revenue | 3.87 | 3.87 | 0.79 | 1.94 | 1.06 | 1.23 |
| 830.53 | 844.54 | 827.4 | 727.41 | 738.02 | 789.73 | |
Revenue Growth (YoY) | -1.80% | 2.07% | 13.75% | -1.44% | -6.55% | -8.95% |
Cost of Revenue | 627.39 | 634.9 | 663.8 | 653.22 | 627.75 | 573.41 |
Gross Profit | 203.14 | 209.64 | 163.6 | 74.18 | 110.27 | 216.33 |
Selling, General & Admin | 82.37 | 79.62 | 76.78 | 74.1 | 73.84 | 104.28 |
Research & Development | 53.6 | 53.67 | 43.76 | 42.92 | 37.42 | 39.64 |
Other Operating Expenses | 9.91 | 8.64 | 6.05 | 8.47 | 8.63 | 11.02 |
Operating Expenses | 145.75 | 142.57 | 132.06 | 128.66 | 120.34 | 155.84 |
Operating Income | 57.39 | 67.07 | 31.54 | -54.48 | -10.07 | 60.49 |
Interest Expense | -0.77 | -0.91 | -2.08 | -1.54 | -4.56 | -5.76 |
Interest & Investment Income | 12.28 | 10.52 | 8.67 | 8.81 | 15.28 | 24.47 |
Currency Exchange Gain (Loss) | -2.44 | -2.44 | 4.1 | 3.86 | 22.76 | -5.27 |
Other Non Operating Income (Expenses) | -4.15 | -0.23 | -0.21 | -0.3 | -0.3 | -0.77 |
EBT Excluding Unusual Items | 62.31 | 74.01 | 42.02 | -43.63 | 23.11 | 73.16 |
Gain (Loss) on Sale of Investments | 0.05 | 0.05 | 0 | 0 | -0.9 | 0.01 |
Gain (Loss) on Sale of Assets | -0.39 | -0.48 | 0.15 | 0.2 | 0.09 | 0 |
Asset Writedown | 2.07 | -0.38 | -0.29 | -12.21 | -0.1 | -1.52 |
Legal Settlements | - | - | -8.1 | - | - | - |
Other Unusual Items | 6.93 | 6.93 | 15.31 | 10.33 | 14.32 | 8.39 |
Pretax Income | 70.97 | 80.13 | 49.09 | -45.31 | 36.52 | 80.04 |
Income Tax Expense | 9.81 | 10.86 | 11.83 | 8.89 | 6.09 | 8.22 |
Earnings From Continuing Operations | 61.16 | 69.26 | 37.26 | -54.2 | 30.44 | 71.82 |
Minority Interest in Earnings | -7.54 | -7.11 | -7.83 | 0.14 | 1.05 | 3.93 |
Net Income | 53.62 | 62.16 | 29.42 | -54.06 | 31.48 | 75.76 |
Net Income to Common | 53.62 | 62.16 | 29.42 | -54.06 | 31.48 | 75.76 |
Net Income Growth | 13.31% | 111.24% | - | - | -58.44% | -61.63% |
Shares Outstanding (Basic) | 183 | 178 | 173 | 169 | 175 | 172 |
Shares Outstanding (Diluted) | 183 | 178 | 173 | 169 | 175 | 172 |
Shares Change (YoY) | 9.40% | 2.60% | 2.45% | -3.41% | 1.59% | 2.03% |
EPS (Basic) | 0.29 | 0.35 | 0.17 | -0.32 | 0.18 | 0.44 |
EPS (Diluted) | 0.29 | 0.35 | 0.17 | -0.32 | 0.18 | 0.44 |
EPS Growth | 3.57% | 105.88% | - | - | -59.09% | -62.39% |
Free Cash Flow | 13.99 | -6.8 | -21.97 | -181.51 | -22.54 | -25.5 |
Free Cash Flow Per Share | 0.08 | -0.04 | -0.13 | -1.07 | -0.13 | -0.15 |
Dividend Per Share | 0.100 | 0.100 | - | 0.060 | 0.060 | 0.140 |
Dividend Growth | - | - | - | - | -57.14% | -60.00% |
Gross Margin | 24.46% | 24.82% | 19.77% | 10.20% | 14.94% | 27.39% |
Operating Margin | 6.91% | 7.94% | 3.81% | -7.49% | -1.36% | 7.66% |
Profit Margin | 6.46% | 7.36% | 3.56% | -7.43% | 4.27% | 9.59% |
Free Cash Flow Margin | 1.68% | -0.80% | -2.66% | -24.95% | -3.05% | -3.23% |
EBITDA | 133.15 | 142.49 | 105.64 | 17.58 | 57.63 | 131.39 |
EBITDA Margin | 16.03% | 16.87% | 12.77% | 2.42% | 7.81% | 16.64% |
D&A For EBITDA | 75.76 | 75.43 | 74.1 | 72.06 | 67.69 | 70.9 |
EBIT | 57.39 | 67.07 | 31.54 | -54.48 | -10.07 | 60.49 |
EBIT Margin | 6.91% | 7.94% | 3.81% | -7.49% | -1.36% | 7.66% |
Effective Tax Rate | 13.83% | 13.56% | 24.10% | - | 16.66% | 10.27% |
Revenue as Reported | 830.53 | 844.54 | 827.4 | 727.41 | 738.02 | 789.73 |
Advertising Expenses | - | 1.89 | 2.04 | 1.27 | 0.65 | 0.37 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.